Efalizumab-induced aseptic meningitis [3];Meningitis aséptica por efalizumab

Farmacia Hospitalaria

Volumn 31, Issue 1, 2007, Pages 70-71

  Rivas Rodriguez R ^a   Romero Alonso, M M ^a   Gabella Bazarot, E ^a   Sanchez Gomez E ^a  

^a HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; EFALIZUMAB; METOCLOPRAMIDE; PARACETAMOL; TRAMADOL; ZOLMITRIPTAN;

ADULT; ANAMNESIS; ASEPTIC MENINGITIS; CASE REPORT; CLINICAL FEATURE; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; LABORATORY TEST; LETTER; MALE; MEDICAL EXAMINATION; PSORIASIS; PUVA; TUBERCULIN TEST;

ADULT; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; HUMANS; MALE; MENINGITIS, ASEPTIC; PSORIASIS;

EID: 34247370116     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Ficha técnica de Raptiva®. Laboratorio Serono Europe. 20 de septiembre 2004.
2. Efalizumab. Ficha de novedad terapéutica. Centro Andaluz de Información de Medicamentos, no 3. 2006.
3. Lebwhol M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13.
4. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-8.
5. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52: 425-33.
6. a ed. Hospital Universitario 12 de Octobre. Madrid; 2003. p. 511-9.
7. th ed. Madrid: McGraw-Hill; 2003. p. 850-1.
8. The Medicines and Healthcare products Regulatory Agency (MHRA). United Kingdom. Consultado 17/11/2006. Available at: http://www.mhra.gov.uk/home/ groups/public/documents/sentineldocuments/dap_ 1130235939475.pdf